Identification and validation of seven genes, as potential markers, for the differential diagnosis of small B cell lymphomas (small lymphocytic lymphoma, marginal zone B cell lymphoma and mantle cell lymphoma) by cDNA macroarrays analysis Leukemia (2002Leukemia ( ) 16, 2326Leukemia ( -2329Leukemia ( . doi:10.1038 TO THE EDITOR Non-follicular small B cell lymphomas refer to a group of clonal proliferations of mature B cells. The most frequent non-follicular small B cell subtypes are B cell small lymphocytic lymphoma/chronic lymphocytic leukemia (B-SLL/CLL), marginal zone B cell lymphoma (MZL) and mantle cell lymphoma (MCL). In their typical forms, B-SLL/CLL, MZL and MCL are characterized by distinctive histological and cytological morphology, immunophenotype and cytogenetic abnormalities. However, in spite of this multifaceted characterization, the reliability of diagnosis is quite variable, ranging from 53% to 94%.
In this study, our objective was to identify new diagnostic markers to better characterize and discriminate non-follicular small B cell lymphomas using cDNA macroarray analysis (Atlas Human Cancer cDNA expression arrays, No. 7742-1, Clontech Lab, Palo Alto, CA, USA). The results were validated with the quantification of the candidate genes by quantitative real-time PCR.
Macroarray data were available from 14 untreated patients: five B-SLL/CLL, five splenic MZL and four MCL. For this macroarray analysis, lymphoma B cells were obtained from fresh blood samples with significant blood involvement (Ͼ40% of the white cells). Peripheral blood mononuclear cells were first isolated using a centrifugation gradient method (Lymphoprep, Gibco BRL, Grand Island, NY, USA). A double isolation procedure was then used to ensure a high degree of purity (greater than 95%) of B cells through: (1) a selective depletion of monocytes/macrophages and NK cells using L-leucine methyl ester, followed by (2) a depletion of T cells performed using an immunomagnetic bead depletion. Total RNA was immediately extracted from the isolated B cells and subjected to DNAse I treatment to minimize genomic DNA contamination (MessageClean kit, GenHunter, Nashville, TN, USA). cDNA synthesis with radioactive labelling, hybridization and washing of the cDNA array membranes were carried out according to the manufacturer's instructions. Photomicrographic data of arrays were analyzed using specific software (AtlasImage 1.0, Clontech) comparing the expression profiles between the three groups of patients with B-SLL/CLL, splenic MZL or MCL. The values were normalized by equalizing the intensity of the signals from a global view. The results showed that the patterns of expression were remarkably similar between the three type of diseases. Indeed, most of the genes (93/100 transcripted genes, 99%) present on the macroarray had similar levels of expression. Out of the 100 (17%) transcripted genes, only seven genes (bcl2, bcl1, mmp17, a3 type IV collagen, notch2, upar and timp1) were found to be expressed at different levels Validation by quantitative real-time PCR was performed in 45 patients that included 20 B-SLL/CLL, 15 splenic MZL and 10 MCL ( Table 1 ). The quantitative real-time PCR was realized on a dilution of the cDNA obtained from 1 g of total RNA of 40 patients (including eight samples of those 14 tested on the macroarrays) and normal B cells isolated from three fresh reactive tonsils used as control. All PCR primers and Taqman probes, labelled with the reporter dye FAM at the 5Ј end and the quencher dye TAMRA at the 3Ј end, were designed with Primer express software program (version 1.0 ppd: Perkin Elmer/Applied Biosystems, Courtaboeuf, France) using published sequence data from the NCBI database. In order to normalize for differences in sample concentration due to variations in mRNA extraction, cDNA synthesis and in sample loading, we also quantified the level of porphobilinogen deaminase (pbgd) used as endogenous reference RNA control. To allow the relative expression of each target gene to be compared across all of the tested samples, sample target gene-pbgd expression was also normalized to the target gene-pbgd values concomitantly measured in the normal B cells from reactive tonsils (calibrator). Levels of the gene transcripts between the different groups of lymphoma (B-SLL/CLL, splenic MZL and MCL) and the normal B cells were compared using the Kruskal-Wallis test when the differences in gene expression were compared in the three diseases, and the Mann-Whitney U test when comparing between two diseases. P values Ͻ0.05 were considered to indicate significant statistical differences. The results showed all selected genes, except one (a3 type IV collagen), to be differentially expressed as observed in the macroarrays data ( Figure 2 ). The relative amounts of bcl2 and mmp17 mRNA were significantly increased in B-SLL/CLL compared to splenic MZL and MCL. In contrast, notch2 expression was significantly increased in splenic MZL but not in B-SLL/CLL and MCL, and upar and timp1 expressions were significantly increased in MCL. We observed a considerable heterogeneity in the relative amount of a3 type IV collagen mRNA inside the three groups.
This study identifies for the first time seven genes, out of 588, differentially expressed in indolent non-follicular B cell lymphomas. These seven gene markers allow the three major subtypes (B-SLL/CLL, splenic MZL, MCL) of non-follicular small B cell lymphoma to be distinguished through a specific expression profile. Several lines of evidence, obtained by macroarrays and validated by quantitative realtime PCR, back the above statement: (1) relative amounts of bcl2 and mmp17 mRNA were significantly increased in B-SLL/CLL compared to splenic MZL and MCL; (2) notch 2 mRNA was significantly increased in splenic MZL compared to B-SLL/CLL and MCL; (3) upar and timp1 were increased in MCL compared to B-SLL/CLL and splenic MZL; (4) a3 type IV collagen showed heterogeneity between the three subgroups of patients. These results allow us to distinguish B-SLL/CLL, splenic MZL, and MCL by analyzing differential mRNA expression level in a limited set of genes.
BCL-2 is an oncogenic protein, which plays an prominent role in controlling apoptosis. The chromosomal translocation t(14;18) with the consequence of an overexpression of the bcl2 gene has been associated with a specific lymphoma subtype, the follicular non-Hodgkin's lymphoma. Apoptotic dysregulation, rather than a cell cycle dysregulation, has been reported to be a major feature in CLL, and abnormal levels of bcl2 gene have commonly been reported in this disease. The mechanism of bcl2 gene overexpression in CLL is different from the gene rearrangement involved in follicular lymphoma since the translocation t(14;18) is exceptionally reported in CLL. With a quantitative real-time PCR method, we confirmed that all the three groups had an elevated expression of bcl2 mRNA compared to normal B cells, but
Figure 1
Representative macroarray photomicrographs for gene markers. The cDNA hybridization patterns for differentially expressed genes are shown for one given patient in each group. Results were similar in all patients in each group. with a significantly higher level in CLL compared to splenic MZL and MCL. However, it is well reported that phenotypic expression of BCL-2 is dysregulated in many low-grade lymphomas, and is not useful in distinguishing non-follicular small B cell lymphomas in routine practice.
Among the six other genes differentially regulated, three were related to interactions with the extracellular matrix (ECM): a protease (mmp17), a protease receptor (upar), and a protease inhibitor (timp1). This high proportion of ECM-related genes identified in our study underscores the importance of the role of the ECM in the pathophysiology of lymphoid malignancies. Elevated TIMP1 expression has been described to be strongly correlated with an aggressive histologic subtype of lymphoma and associated with a poor prognosis. None of the previous studies in the literature have reported a specific correlation of TIMP1 with mantle cell lymphoma. Our report showed a significantly higher level of expression of timp1 in mantle cell lymphoma, the prognosis of which is generally poor. We did not observe any expression of mmp9 in the macroarray analysis. MMP9 expression has been described both in indolent as well as in aggressive lymphoma subtypes, with higher levels in the aggressive subtypes and with a correlation with a poor survival, independently or in association with TIMP1.
MMP17 is the protease that we identified as being differentially expressed in indolent lymphomas, with a significant overexpression in CLL. MMP17 is a membrane-inserted MMP (MT4-MMP), whose enzymatic function has been recently reported to be different from the other MT-MMPs, without any pro-MMP-2 activity. MMP17 could be involved in the activation of membrane-bound growth factor or inflammatory mediators such as tumor necrosis factor-alpha. mmp17 transcript has been detected in breast carcinoma, and has never yet Leukemia been reported in hematologic malignancies. The mmp17 gene is located within the long arm of chromosome 12, which is involved in one the most frequent chromosomal abnormalities in CLL, the trisomy 12q. However, none of the CLL patients tested by quantitative realtime PCR had a trisomy 12, leading us to believe that the mechanism of mmp17 overexpression is not due to an excess of genetic material but to another type of over-regulation, possibly involving its methylation status.
The upar gene codes for the receptor of a key protease, the urokinase-type plasminogen activator (uPA), located within the 19q13 locus. uPAR is known to play important roles in tumor cell migration, invasion and metastasis. High levels of uPA, uPAR and the inhibitor PAI1 have been described to predict poor prognosis in many solid tumors, particularly in breast cancer where they represent independent prognostic factors for survival.
The notch2 gene encodes a 300 kDa single pass transmembrane receptor, belonging to the Notch/Lin-12/Glp-1 receptor family, and participates in cell-cell signaling events that influence cell fate decisions. Notch genes control cell fate by inhibiting cellular differentiation, presumably through activation of the transcriptional regulator human C promoter binding factor (CBF1), which transactivates the target gene, hairy and Enhancer of split (HES-1) gene. The result of Notch signaling is to preserve a small population of uncommitted multipotent cells within a differentiating tissue. Truncated active forms of Notch have been shown to have an oncogenic activity in acute T cell lymphoblastic leukemia/lymphoma and in the transformation of kidney epithelial cells. Notch2 could also be implicated in the pathogenesis of the CLL through a dysregulation of the expression of the B cell activation marker CD23. We effectively showed that notch2 was overexpressed in B-SLL/CLL when compared to normal B cells, but a Some of the samples were used in both experiments, macroarray hybridization and quantitative real titime PCR. Forty-eight patients were selected after histological, cytological, immunological and cytogenetic (conventional cytogenetic and fluorescent in situ hybridization) analyses, completed on tissue obtained from spleen for all MZL patients, and from nodes for all MCL patients, providing a diagnosis of typical B-SLL/CLL, splenic MZL, or MCL according to the WHO classification criteria. For the B-SLL/CLL cases, diagnosis was assessed by the analyses of the blood samples. All cases were reviewed by two specialized pathologists (FB and PF). All patients were informed on the conservation of biological samples for research studies and provided their informed consent. Blood samples were drawn from 39 untreated patients with small B cell lymphoma with significant peripheral blood involvement (Ͼ40% of total white blood cells). MCL is a rare disease, particularly when considering patients with significant leukemic forms. Over the period of our study, only four patients presented in our department with leukemic mantle cell lymphoma with a sufficient number of lymphoma cells to obtain at least 10 g of total RNA. These latter samples were used in priority for the macroarray hybridization analyses. For the validation of candidate gene expression by real-time PCR, the same B-SLL/CLL and MZL cases were used as for the macroarray analyses whereas nine other cases of MCL were studied, including frozen samples of nodal MCL. splenic MZL samples expressed notch2 at a very high level, with a significant difference in comparison with B-SLL/CLL and MCL.
Microarray technology provides a powerful tool to assess the expression of a large number of genes in a single experiment. Several studies have demonstrated the ability of this technique to characterize gene expression profiles specific to a given cell population, with the aim to identify profiles relevant for diagnosis and prognosis 2, 3 or to identify novel tumor-specific markers for certain malignant diseases. 5 We used cDNA arrays to better characterize a heterogeneous group of lymphomas, non-follicular small B cell lymphomas. Our study confirms that gene expression profiling can identify parameters related to the heterogeneity of lymphoma and allows the differentiation of lymphoma subtypes. The diagnostic potential of a genomic-based analysis has already been reported in diffuse large B cell lymphomas (DLBL). 3, 6 Alizadeh et al 3 used lymphoid-specific cDNA arrays to identify two different subtypes of DLBL with different putative cells of origin (germinal center cells vs peripheral activated B cells) and demonstrated a correlation between cell of origin and outcome. In the second study, Shipp et al 6 analyzed the expression of an unselected set of 6817 genes related to cell adhesion, apoptosis, ras signaling, serine/threonine phosphorylation and tumor immunity using an Affymetrix microarray to predict different outcomes for DLBL patients. In CLL, two recently published studies focused on genomic 7 and proteomic profiles 8 and identified distinct sets of candidate genes. The numerous studies using these large-scale expression profiling technologies focusing on different issues are generating large amounts of data underscoring the power of this technique in medical research. However, these data are heterogeneous, both in terms of patient characteristics and in the way they are obtained using different array technologies. It therefore will be necessary to develop public resources, containing standardized different data sets obtained from different sources as proposed by the MGED group (http://www.mged.org).
In conclusion, we have demonstrated in this study that B-SLL/CLL, MZL and MCL possess specific transcriptional profiles that may be relevant to the pathogenesis of these histological subtypes. With a small set of genes, we are able to better identify this heterogeneous group of lymphoma. cation-generated mutations in the DNA binding runt domain have recently been reported in some cases of AML and MDS. [2] [3] [4] [5] [6] This new molecular lesion seems to be particularly frequent in M0-AML. Furthermore, Song et al 6 described the presence of AML1 mutations in a familial platelet disorder with a predisposition to develop AML (FDP/AML). In this work, we analyzed a consecutive series of myeloid malignancies and we found two new mutations which were localized outside of the runt domain of the AML1 gene.
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A total of 30 patients with acute leukemia or MDS diagnosed following the FAB criteria were included in the study, as follows: M1 n = 4, M2 n = 5, M3 n = 1, M4 n = 3, M5 n = 9, CMML n = 1, RAEB and RAEBt n = 5 and hypoplastic AML n = 2 including one case of therapy-related AML. There were 20 males and 10 females with a median (range) age of 49.6 (10-84) years.
